Bicetre Hospital
- Address
- 78 Rue Du General Leclerc, 94275 Le Kremlin-Bicetre, France
Rheumatology and Pediatric Inflammatory Disease Research
At Bicetre Hospital, the Service de Rhumatologie is involved in studies focused on immune system diseases and skin and connective tissue diseases, with a strong emphasis on inflammatory conditions in children and adolescents. The research is designed to better understand and improve care for juvenile idiopathic arthritis and related forms of arthritis.
- Studies in juvenile idiopathic arthritis and related pediatric arthritis conditions
- Research on enthesitis-related arthritis and juvenile psoriatic arthritis
- Evaluation of new treatments aimed at improving symptom control and disease outcomes
These trials are helping assess how well emerging therapies work in young patients living with chronic inflammatory joint disease.
Autoimmune and Systemic Disease Studies
Clinical research at this site also covers immune system diseases and broader immune system phenomena, including work on complex autoimmune conditions such as Sjögren’s syndrome. The goal is to improve treatment options for people with moderate to severe systemic disease activity.
- Research in Sjögren’s syndrome with systemic involvement
- Studies examining control of broader autoimmune symptoms and organ-related effects
- Testing whether new therapies can reduce disease activity and improve daily functioning
This area of research reflects a focus on treatments that may better address the full impact of systemic autoimmune disease.
Neurology-Related Amyloidosis Research
The trial portfolio at Bicetre Hospital includes research in nervous system diseases and rare inherited disorders, especially hereditary transthyretin-mediated amyloidosis with polyneuropathy. These studies aim to determine whether new therapies can help preserve nerve function and reduce neurologic impairment.
- Investigation of hereditary transthyretin-mediated amyloidosis with polyneuropathy
- Assessment of treatments intended to slow nerve damage and improve neurologic outcomes
- Rare disease research with a focus on symptom relief and disease control
This work supports efforts to improve care for patients affected by a progressive inherited condition that can strongly affect the nerves.
Translational Pediatric Rheumatology and Treatment Evaluation
Across its clinical studies, the site contributes to research that spans congenital, hereditary, and neonatal diseases and abnormalities as well as inflammatory conditions linked to the immune system. The trials are centered on understanding how therapies behave in younger patients and on evaluating their effectiveness in real clinical settings.
- Drug behavior and treatment response research in children and adolescents
- Clinical evaluation of therapies for inflammatory joint disease
- Studies aimed at improving long-term disease management and patient outcomes
This research profile highlights a mix of pediatric rheumatology, autoimmune disease, and rare disease studies, showing a broad interest in improving care for both common and uncommon conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 19 therapeutic areas and 15 of 95 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 90 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 34 by active trials.
- 1F. Hoffmann-La Roche AG3active
lock +33 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1F. Hoffmann-La Roche AG5trials
lock +9 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Bicetre Hospital
lock Showing 1 of 65 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized Open-Label Study of Imetelstat Versus Best Available Therapy in Intermediate-2 or High-Risk Myelofibrosis Refractory to JAK-Inhibitors | Geron Corp. | Phase III | Not Recruiting | Apr 2021 | — |
IMP list
lock Showing 1 of 95 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Filgotinib | 3 | Unknown | 2024-02-14 | 2026-04-13 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
